St. Jude Medical (STJ) Releases Earnings Results, Misses Expectations By $-0.02 EPS

St. Jude Medical (STJ) announced its most recent quarterly financial results on Wednesday, Oct-19-2016. STJ reported $0.99 earnings per share for the quarter, missing the analyst consensus estimate by $-0.02. Analysts had a consensus of $1.01. The company posted revenue of $1499.00 million in the period, compared to analysts expectations of $1498.08 million. STJ’s revenue was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.97 EPS.

St. Jude Medical closed down -0.18 points or -0.23% at $77.98 with 14,22,465 shares getting traded on Friday. Post opening the session at $78.4, the shares hit an intraday low of $77.94 and an intraday high of $78.71 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

In a different news, on Feb 9, 2016, Jeff Fecho (VP, Global Quality) sold 10,408 shares at $51.71 per share price. According to the SEC, on Dec 22, 2015, John C Heinmiller (Executive Vice President) sold 8,009 shares at $61.16 per share price. On Dec 22, 2015, Jeff Dallager (VP and Corporate Controller) sold 501 shares at $60.94 per share price, according to the Form-4 filing with the securities and exchange commission.

St. Jude Medical Inc. develops manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management cardiovascular and atrial fibrillation therapy areas and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders. Its six principal product categories include tachycardia implantable cardioverter defibrillator (ICD) systems bradycardia pacemaker systems atrial fibrillation (AF) products (electrophysiology introducers and catheters advanced cardiac mapping navigation and recording systems and ablation systems) vascular products (vascular closure products pressure measurement guidewires optical coherence tomography (OCT) imaging products heart failure monitoring device and other vascular accessories) structural heart products and neuromodulation products (spinal cord stimulation and radiofrequency ablation to treat chronic pain and deep brain stimulation to treat movement disorders).

St. Jude Medical

Leave a Reply

St. Jude Medical - Is it time to Sell?

Top Brokerage Firms are advising their investors on St. Jude Medical. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.